News

New tests within Neurology

July 18, 2014 - Company News, Product News, Disease Area News
Wieslab introduces a whole new range of interesting neurology markers. Some of the markers have been included as a result of feedback from customers, and we would like to thank you for this contribution. The update of the request form also marks the introduction of the first genetic markers at Wieslab and we will soon offer more testing opportunities in this area.

 

The updated request form is available for download here.

Test packages and details

Narcolepsy

- Sequencing of HLA-DQB1 * 0602, orexin / hypocretin level in CSF, and antibodies against Trib2 - Over 90% of individuals with narcolepsy with cataplexy carry the genetic marker HLA-DQB1 * 0602 and orexin levels are usually significantly reduced in individuals with narcolepsy. Antibodies against Trib2 have been detected in up to 30% of patients with narcolepsy with cataplexy. A form for special informed consent is required for genetic HLA analysis and can be downloaded here.

Multiple Sclerosis Biomarkers

- Neurofilament light protein (NFL), CXCL13 - NFL in CSF is a general marker of brain injury that can be used as a measure of disease progression. CXCL13 is an important chemokine and biomarker in CSF, with a strong association to neuroinflammation and B cell infiltration.

Autoimmune myositis

Analysis of antibodies in myositis has previously been on Wieslab’s request form for autoimmune diagnostics and has now also been included on the neurology request form together with an expanded panel of myositis antibodies with a low prevalence.

- Standard package (ANA screen, ENA screen (nRNP / Sm, Sm, SS-A/Ro-52, SS-B, Scl-70, Jo-1) antibodies to PL-7, PL-12, EJ, PM / Scl, Mi-2, SRP))

- Extended analysis package (Antibodies against OJ, KS, KU, Tryptophanyl-tRNA synthetase, RNA polymerase I, II, II)

New individual tests

- Lrp4 antibodies - Antibodies to lipoprotein receptor-related protein 4 (LRP4) have been identified in Myasthenia Gravis patients who are seronegative for both Acetylcholine receptor and MuSK antibodies. The frequency of an international study (635 patients) was 18.7%, but with a large variation between different populations (7 to 32.7%). The variation could not be linked to any geographic pattern.

- Aquaporin 1 antibodies - These antibodies have been detected in a subpopulation of patients having a milder form of myelitis with symptoms that are not typical for Neuromyelitis Optica.

- Ganglioside antibodies are now tested using and ELISA, both for serum and for CSF.

 

Did you know that Wieslab also has the ability to analyze samples acute in cases of suspected encephalitis Autoimmune and Paraneoplastic Syndrome?

Please contact us for more information. As always, feel free to contact us if you would like us to come and visit you for an introduction of our laboratory.

We take the opportunity to wish all our customers and partners a great summer!

 

Anna Laurén, PhD

Wieslab Laboratory Manager

T: +46 40 53 76 52

M: +46 70 274 34 82

anna.lauren@wieslab.com or

anna.lauren@eurodiagnostica.com

« Back
Clinical studies